Cato T. Laurencin - Dec 8, 2023 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
Director
Signature
/s/ Shantale Greenson, attorney-in-fact for Cato T. Laurencin
Stock symbol
ALKS
Transactions as of
Dec 8, 2023
Transactions value $
$1,097
Form type
4
Date filed
12/12/2023, 08:46 PM
Previous filing
Jul 10, 2023
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +4.16K +34.67% 16.2K Dec 8, 2023 Direct F1
transaction ALKS Ordinary Shares Tax liability -$25.9K -1K -6.18% $25.86 15.2K Dec 8, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $2.52K +112 +2% $22.52 5.71K Nov 17, 2023 Ordinary Shares 112 $22.52 Direct F2, F3
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $9.5K +422 +2% $22.52 21.5K Nov 17, 2023 Ordinary Shares 422 $22.52 Direct F2, F4
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7.13K +231 +2% $30.86 11.8K Nov 17, 2023 Ordinary Shares 231 $30.86 Direct F2, F5
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7.8K +254 +1.99% $30.72 13K Nov 17, 2023 Ordinary Shares 254 $30.72 Direct F2, F6
transaction ALKS Restricted Stock Unit Award Other +119 +1.99% 6.1K Nov 17, 2023 Ordinary Shares 119 Direct F1, F2, F7
transaction ALKS Restricted Stock Unit Award Other +163 +2% 8.33K Nov 17, 2023 Ordinary Shares 163 Direct F1, F2, F8
transaction ALKS Restricted Stock Unit Award Options Exercise -4.16K -50% 4.16K Dec 8, 2023 Ordinary Shares 4.16K Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F3 This award is fully vested in accordance with its terms.
F4 Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022.
F5 These options are fully vested in accordance with their terms.
F6 Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
F7 Shares subject to the restricted stock unit award vest in full on 6/29/2024.
F8 Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022.